ライフサイエンスコーパス: subgroup

1 I), 1.45; 95% CI, 1.07-1.96 for non-diabetic subgroup).

2 racoronary alteplase may be harmful for this subgroup.

3 studies in the proportions of people in each subgroup.

4 years to/from actual onset in a symptomatic subgroup.

5 ith the addition of PCV in the IDH-wild-type subgroup.

6 age, 12 years +/- 6; four male) were in the subgroup.

7 nergy x-ray absorptiometry measurements in a subgroup.

8 ethylation profiling belonged to the SHH-INF subgroup.

9 e preclinical compared with the neurotypical subgroup.

10 lly significant across most sociodemographic subgroups.

11 revealed between the phenotype and genotype subgroups.

12 vs tractional (P = .002) and FTMH (P < .001) subgroups.

13 ars in both postmenopausal and premenopausal subgroups.

14 ines also showed OXPHOS(high) or OXPHOS(low) subgroups.

15 rker-defined Parkinson's disease participant subgroups.

16 of inflammatory markers and persisted across subgroups.

17 enG was superior to GClb across most genetic subgroups.

18 of PTSD across all studies, and then within subgroups.

19 nces in TCRS were observed between the three subgroups.

20 d INPC criteria will identify new prognostic subgroups.

21 h of the TAVR (P<0.0001) and SAVR (P<0.0001) subgroups.

22 d blood eosinophil (<250 and >=250 cells/uL) subgroups.

23 ient longevity, particularly among high-risk subgroups.

24 ality of surgery was significant across most subgroups.

25 antial differences were seen between patient subgroups.

26 characterise effects in clinically important subgroups.

27 distinct, but DDX3X is often mutated in both subgroups.

28 ection remained very low (<0.25%) across all subgroups.

29 tantly, we identify a genomically defined MM subgroup (17% of newly diagnosed patients) with low DNA

30 noninvasive testing alone, was applied to a subgroup (2009-2010) from that study.

31 ignificant difference in obese and non-obese subgroups (42.5% vs 49.6% respectively; p=non-significan

32 For the LGI1-IgG seropositive subgroup, 6 of 8 patients in the IVIG group were respond

33 higher in the prespecified exploratory MRSA subgroup (74.1% vs. 31.3%, difference = 42.8, 90% CI [14

34 S in the clinical high and genomic high-risk subgroup (86.1% v 88.1%; HR, 0.83 [95% CI, 0.58 to 1.21]

35 ics and disease characteristics of the Asian subgroup (87/302 patients) were generally well balanced

36 Here, we characterize a land plant specific subgroup 9 R2R3 MYB transcription factor MpSBG9, in the

37 r of LNM at baseline was 5-7 cm in 101 (34%; subgroup A) and 8-10 cm in 96 (32%; subgroup B), whereas

38 When analysed separately for the three WHO subgroups, a similar association was only retained in as

39 ome, the patients were prespecified into two subgroups according to concomitant autoimmune disease st

40 Subjects are classified into three subgroups according to histological spectra of NAFLD or

41 thin a schizophrenia sample and profiled the subgroups across polygenic scores (PGSs) for schizophren

42 This subgroup allowed us to distinguish patients with low- an

43 The two subgroups also differed in terms of their transcriptiona

44 roup in all prespecified clinicopathological subgroups analysed, with similar HRs to that for the bro

45 Prespecified subgroup analyses and safety analyses were conducted.

46 Subgroup analyses by disease state found statistically s

47 We performed subgroup analyses by treatment or types of FLAIR-HAs def

48 Prespecified subgroup analyses for the primary outcome showed a signi

49 Pre-planned subgroup analyses included regimen and risk group.

50 ol (PP) analyses were undertaken, along with subgroup analyses of >=75% compliant patients, to compar

51 Pre-specified subgroup analyses of gender, ferritin < 25 ug/L and fati

52 Subgroup analyses revealed a significant beneficial impa

53 Meta-regression and subgroup analyses revealed that left ventricular ejectio

54 Subgroup analyses showed disorder-specific gray matter a

55 Subgroup analyses showed that hypertensive participants

56 Subgroup analyses were conducted for 10 variables; the t

57 Prespecified subgroup analyses were conducted for parity (nulliparous

58 Subgroup analyses were conducted using income quartiles

59 Pre-specified subgroup analyses were performed based on prior HF histo

60 Subgroup analyses were performed for sex, sample size, d

61 Prespecified subgroup analyses were performed.

62 In subgroup analyses, AF discrimination using EHR-AF was lo

63 In subgroup analyses, better treatment outcomes at Months 3

64 In univariable analyses and subgroup analyses, OS and the cumulative incidence of re

65 In subgroup analyses, the AUC was 0.95 (95% CI: 0.94 to 0.9

66 ere defined from each study and prespecified subgroup analyses.

67 Subgroup analysis according to management yielded a pool

68 In subgroup analysis among symptomatic patients, the risk o

69 Subgroup analysis by the geographical regions showed in

70 Subgroup analysis in standard 5-year age categories was

71 A subgroup analysis of 11 patients with prior (177)Lu-PSMA

72 A prespecified subgroup analysis of elderly patients with myocardial in

73 In a subgroup analysis of post-treatment MRIs in post-chemora

74 These results remained significant in the subgroup analysis of small aneurysms (width <= 3 mm) and

75 At subgroup analysis of surgically excised lesions, the poo

76 In the prespecified subgroup analysis of the full analysis set stratified by

77 Subgroup analysis on patients with IPMNs confined to the

78 Other subgroup analysis results show that NINMs effects are hi

79 Subgroup analysis showed that this association was modif

80 A subgroup analysis was performed to assess the gadobenate

81 In the subgroup analysis with unilobar metastatic patients, aga

82 In the subgroup analysis, in-hospital mortality was lower in pa

83 In a subgroup analysis, RT-RPA detected 9/10 RT-qPCR-positive

84 In a prespecified subgroup analysis, treatment within 7 days after symptom

85 In this subgroup analysis, we focused on the safety and activity

86 In this prespecified subgroup analysis, we included 1653 patients with ST-seg

87 In subgroup analysis, young age, male sex, and relatively h

88 n naive to surgeon, surgery, and outcome for subgroup analysis.

89 patient survival was superior for all 3 KDPI subgroups analysis.

90 the sonic hedgehog medulloblastoma (MB(SHH)) subgroup and accounted for 5% of infant MB(SHH) cases in

91 for the protocolized physical rehabilitation subgroup and enhanced in patients with longer ICU stay a

92 ation = 7 149 888); local HCV CVLs varied by subgroup and geography.

93 Subgroup and sensitivity analyses were conducted using a

94 s of CKD across different clinically defined subgroups and are characterized by high genetic and phen

95 edictive impact of the WHO-defined molecular subgroups and corresponding molecular alterations within

96 ory of cognitive recovery across ICU patient subgroups and determine which acute illness and treatmen

97 tionships associated with different exposure subgroups and different lung cancer subtypes.Objectives:

98 d quantitative metrics were compared between subgroups and normal control subjects.

99 maintenance and recurrence across individual subgroups and subtypes.

100 model parameters for primary and metastatic subgroups and that correlation coefficients were superio

101 NCB was particularly favorable in high-risk subgroups and those with multiple risk characteristics.

102 eveals that EBV type 2 exists as two genomic subgroups and was more commonly found in female than in

103 only be detected very occasionally in all AF subgroups and were not locatable in patients with SR.

104 ection subtypes and demographic and clinical subgroups, and remained significant after additional adj

105 istically significant in the above-mentioned subgroups, and such association was not documented in th

106 of analysis for balance assessment: triads, subgroups, and the whole network.

107 The H5 LPAIVs of the HA-III and HA-IV subgroups appeared in 2015 and 2017 in unusually high pr

108 We conducted regression analyses with LGMM subgroups as predictors of response at treatment end.

109 raphic pulmonary angiography (CTPA) rates in subgroups at high risk for adverse imaging outcomes, inc

110 hat walnuts might delay cognitive decline in subgroups at higher risk.

111 01 (34%; subgroup A) and 8-10 cm in 96 (32%; subgroup B), whereas classic bulky (diameter > 10 cm) wa

112 Patients were further subgrouped based on the types of primary bariatric surge

113 tment effects showed consistent benefits for subgroups based on age, sex, diabetes, treatment with an

114 ested treatment-by-subgroup interactions for subgroups based on NYHA functional class and race.

115 isk for first HHF was consistent across most subgroups, but greater benefit of ertugliflozin was obse

116 s association remained true when analyzed in subgroups by pathway location for right and left free wa

117 (diameter > 10 cm) was detected in 99 (33%; subgroup C).

118 Subgroups categorized by initial cardiac rhythm and EMS-

119 Subgroup characteristics converged with genetic patterns

120 entified NOTCH1 significantly increased in a subgroup characterized by distinct stromal infiltration.

121 Calibration was fair in all race-sex subgroups (chi(2)<20).

122 Ophthalmological examinations and phenotype subgroup classification were performed.

123 Non-parametric tests were used for subgroup comparisons based on posting date and character

124 differences were observed between the preset subgroups comprising laser-controlled ROP infants and RO

125 Patients were divided into two subgroups consisting of patients without SLT treatment p

126 The largest subgroup contains the cytochrome c oxidases (CcO), which

127 mivir benefit overall and in 36 prespecified subgroups defined by age, comorbidity, previous symptom

128 t DIPs/Dprs segregate into seven specificity subgroups defined by binding preferences between their D

129 Results were consistent across subgroups defined by ejection fraction, sex, race, cause

130 tine clinical practice with special focus on subgroups defined by sex, race, and ejection fraction.

131 primary and key secondary end points, the US subgroup demonstrated particularly robust risk reduction

132 natures partitions POLE tumors into distinct subgroups dependent on the nature of the POLE allele, it

133 Subgroups derived from patterns of premorbid and current

134 e transcriptomes of eight different monocyte subgroups derived from the brain and the blood of glioma

135 with versus without diabetes mellitus, both subgroups derived similar benefit (2.3% versus 1.4% for

136 rienced a mortality reduction: the non-white subgroup did not.

137 There were no significant subgroup differences.

138 Each subgroup displayed different molecular profiles.

139 In high-dose ICS type 2-high subgroups, dupilumab 200/300 mg q2w vs placebo in the ph

140 event rates were low across sociodemographic subgroups (e.g., CVD rates per 1,000 person-years: age 1

141 limited by small number of events in certain subgroups (e.g., LAA), which could have led to insuffici

142 HPTN 067/ADAPT protocol, was estimated using subgroup efficacy estimates from the preexposure prophyl

143 e patterns, risk behaviours, and susceptible subgroups (eg, PWID experiencing homelessness) needs to

144 liflozin were consistent across the diuretic subgroups examined in DAPA-HF.

145 This held true for all subgroups except blacks, where all 3 measures overestima

146 cts were largely consistent across different subgroups except for intervention functionality and mode

147 This study aimed to determine whether GA subgroups exist that can be defined by their genotype an

148 The white subgroup experienced a mortality reduction: the non-whit

149 ional placebo-controlled trials, overall and subgroup findings were unchanged.

150 esponses were measured at baseline and, in a subgroup, flow cytometry was performed at weeks 2 and 14

151 o their PK parameter values revealed patient subgroups for each drug in which inter-patient variabili

152 serum interleukin-18 response are potential subgroups for further investigation of inhaled IFN-beta1

153 assigned patients with HFrEF and in relevant subgroups from DAPA-HF and EMPEROR-Reduced trials.

154 t groups, in the ITT, PP (172 patients), and subgroup (>=75% compliance, n = 112) analyses.

155 the Eurasian lineage, classified into three subgroups (HA-II, HA-III, and HA-IV).

156 sses molecularly different subgroups, with a subgroup harboring evidence of defective homologous reco

157 Virtually all MM subgroups have activated DNA repair-associated signature

158 Within universally tested subgroups, high percentages of SARS-CoV-2 infected asymp

159 .47 to 0.68) and in the PD-L1-positive tumor subgroup (HR, 0.57; 99% CI, 0.43 to 0.74).

160 the usefulness of biomarker information for subgroup identification enhancing target identification

161 fying supportive care may be appropriate for subgroups identified as being vulnerable to greater toxi

162 ion fraction across a range of racial/ethnic subgroups in a separate testing cohort (n=52 870): non-H

163 izations were consistently higher across all subgroups in comparisons of toxin-positive to toxin-nega

164 vidually or in clusters to define biological subgroups in psychiatry requires a re-orientation from b

165 maintenance of connections within prides and subgroups in the face of ecological change suggests that

166 adership attainment of the two largest Asian subgroups in the United States: East Asians (e.g., Chine

167 We identified patient subgroups in which targeted testing may be effective in

168 The subgroup included 55 neonates with SDH (mean gestational

169 Eligible histological subgroups included diffuse large B-cell lymphoma, high-g

170 The former group is composed of two subgroups, indicating a third introduction.

171 nd baseline eGFR, but suggested treatment-by-subgroup interactions for subgroups based on NYHA functi

172 diotherapy timing on event-free survival and subgroup interactions were combined using fixed-effect m

173 A deviant subgroup is the cytochrome c dependent NO reductases (cN

174 In subgroups, leukocyte homing was blocked by integrin anti

175 ions are making social decisions at both the subgroup level and the pride level, with decisions repre

176 Furthermore, the LAMP3 + DC subgroup may be able to recruit regulatory T cells, pote

177 unctional outcome were assessed from the ICU subgroup.Measurements and Main Results: The study includ

178 xposure measurements may be used to identify subgroup membership, increasing likelihood of linkage.

179 nificantly predicted 7.9% of the variance in subgroup membership.

180 Subgroup multivariate analysis of open PD revealed decre

181 (2) [689-743] and 96.0 mm [94.5-97.9] in the subgroup of 124 patients with extra-large annuli).

182 In the subgroup of 184 patients followed for testosterone recov

183 In a subgroup of 1850 pregnant women, more than 90% of women

184 blood mononuclear cell (PBMC) analysis on a subgroup of 26 IgG-negative participants.

185 A subgroup of 930 individuals underwent spirometry testing

186 The coccidian subgroup of Apicomplexa possesses an apical complex harb

187 ustering of temporal lipidome, identifying a subgroup of children having early onset of each initial

188 Another small subgroup of diagnosed-ALN(-) with ALN(-) immune patterns

189 ealed a significant survival benefit for the subgroup of fast-progressing patients.

190 A 40.6% subgroup of hospitalized patients required neither ICU o

191 -cell replication is strongly increased in a subgroup of human organ donors characterized by prolonge

192 to coronary reperfusion, was a pre-specified subgroup of interest.

193 mote tumor progression in the sonic hedgehog subgroup of medulloblastoma (SHH-MB).

194 -regulated in both Gorlin tNES cells and SHH-subgroup of medulloblastoma patients.

195 nic mouse model for the sonic hedgehog (Shh) subgroup of medulloblastoma, here we evaluated the poten

196 0 MIA and control offspring, we identified a subgroup of MIA offspring that displayed elevated periph

197 ypothesize that fish may adaptively pick the subgroup of neighbors they 'listen to' to determine thei

198 MET exon 14 alteration defines a molecular subgroup of NSCLCs for which MET inhibition with crizoti

199 There is also a rapidly expanding subgroup of patients characterized by a high accumulatio

200 A subgroup of patients had T cell activation characteristi

201 In addition, a subgroup of patients tested with a probabilistic reward

202 typical patterns of dystonia evolution and a subgroup of patients with a non-dystonic neurodevelopmen

203 els of GABA in dorsal ACC (p = .03), and the subgroup of patients with a schizophrenia diagnosis had

204 In a subgroup of patients with advanced chronic kidney diseas

205 to control for tumor burden, we identified a subgroup of patients with an adverse TME associated with

206 The subgroup of patients with an IOP elevation >=2 mmHg had

207 In the subgroup of patients with chronic NALD, the correlations

208 Chest CT features were calculated in a subgroup of patients with positive RT-PCR and CT finding

209 ch improved renal outcomes occur only in the subgroup of patients with proteinuria, indicating podocy

210 tosis (R(S)=0.608, p<0.001); however, in the subgroup of patients with viral hepatitis these correlat

211 In an analysis of a subgroup of patients without esophageal varices at basel

212 Sorafenib leads to clinical benefit in a subgroup of patients, whereas all are exposed to potenti

213 s places SFV in a basal position among a new subgroup of recently recognized aquatic and bat flavivir

214 all uptake of telemonitoring and uptake in a subgroup of representative practices, used routinely acq

215 ry amine substrates allows us to delineate a subgroup of Rieske oxygenases (group V) from the prototy

216 A subgroup of the Diet, Obesity, and Genes (DiOGenes) stud

217 o associated with T2-low asthma phenotype, a subgroup of whom displayed elevations in lung inflammato

218 callous-unemotional (CU) traits designate a subgroup of youth with conduct disorders who have unique

219 rovide insights into the different molecular subgroups of colorectal tumors that develop via each of

220 We identify two consistent subgroups of critical illness based on serum transcripto

221 ification, data-driven analysis identified 4 subgroups of depression cases, 2 of which (n = 38 and n

222 ents based on plasma TNF and KYN/TRP yielded subgroups of high (N = 17) and low (N = 55) TNF-KYN/TRP

223 Subgroups of low, moderate, and high use yielded adjuste

224 nflammatory process defined by individual or subgroups of markers is unclear.

225 ther, our results highlight the existence of subgroups of MIA-exposed offspring that show dissociable

226 ribution and relative importance of specific subgroups of N(2) fixers in the sea; these changes have

227 g together diverse taxa; it holds within all subgroups of organisms we examined as well.

228 hical cluster analysis was used to determine subgroups of participants defined by these features.

229 a dose-response pattern and was observed in subgroups of participants of different occupational posi

230 ring using latent class analysis to identify subgroups of patients on the basis of 12 clinical factor

231 liflozin were consistent in the prespecified subgroups of patients stratified according to the timing

232 neity of depression and potentially to match subgroups of patients to specific treatments with higher

233 Five subgroups of patients with active EoE were identified by

234 ore high quality evidence, preferentially in subgroups of patients with an incidence of SSI>=20% in t

235 stratification capability (P<0.001), even in subgroups of patients with LVEF < or >=50% (P=0.011 and

236 well as in future trials to target specific subgroups of patients.

237 offer the ability to study outcomes of rare subgroups of pediatric VTE (eg, renal vein thrombosis),

238 echanisms of cognitive decline may exist for subgroups of the population, and are associated with the

239 these tools do not work equally well for all subgroups of the population.

240 post hoc analysis combines the pre-specified subgroups of UA and NSTEMI of the randomized ISAR-REACT

241 We assigned people to cognitively defined subgroups on the basis of relative performance in memory

242 arms or examined heterogeneity by population subgroups or assumed treatment effect.

243 381 respectively), nor in specific high-risk subgroups or breast cancer subtypes.

244 id not depend on previously established BRAF subgroups or the consensus molecular subtype.

245 f FLI), 2.89; 95% CI, 1.01-8.27 for diabetic subgroup; OR (highest vs. lowest quartile of FLI), 1.45;

246 had >=1 APOE epsilon4 allele than any other subgroup (overall p = 1.5 x 10(-27)).

247 etic peptide declined significantly in all 4 subgroups (p < 0.001), with greater decreases in the S/V

248 A trial were divided into 4 disease severity subgroups: progression and symptoms, symptoms only, prog

249 In the subgroup receiving metformin, independently from immunos

250 arkers/omic effects while jointly estimating subgroups relevant to the outcome of interest.

251 Representative strains of three HA subgroups replicated restrictively in specific-pathogen-

252 Definition of these subgroups requires the identification of biomarkers in b

253 use (18)F-FDG PET/CT to identify a high-risk subgroup requiring therapeutic intensification among pat

254 D cohort, and BRCA wild-type/LOH low patient subgroup, respectively.

255 al exhaled nitric oxide and blood eosinophil subgroups, respectively) and were sustained through trea

256 itional insights into the details of each HF subgroup's clinical manifestation of HF.

257 Whereas the non-US subgroup showed significant reductions in the primary an

258 In particular the two subgroups showed a significant 27.7% and 28.2% reduction

259 es in the favorable early hypoxia resolution subgroup significantly depended on infiltrating lymphocy

260 show significant associations with molecular subgroups/subtypes, mutations, and prognosis.

261 g to 14.6 +/- 9.4 mmHg, P = 0.30) and in the subgroup that underwent tube explant (15.9 +/- 5.5 mmHg

262 ciation of an exposure with an outcome among subgroups that differ by a set of characteristics.

263 ne learning of ECG waveforms to identify CRT subgroups that may differentiate outcomes beyond QRSd an

264 te a potential influence of cryptic minority subgroups that may illuminate the empirical link between

265 For the subgroup, the mean interval between the first and last f

266 In this subgroup, the ORR was 37% in the treatment arm versus 2%

267 rtality rates were higher in the underweight subgroups, this study was unable to demonstrate that nut

268 d retreatment should be implemented for this subgroup to prevent HCV transmission.

269 tation must take into account individual and subgroup variability in genetic architecture, environmen

270 A higher inflammation subgroup was defined by elevations in a group of 7 marke

271 Thus, evaluation of the ERCC1-high subgroup was limited.

272 ertainty of evidence for glycemic control by subgroup was moderate for multicomponent clinic-based in

273 the ASD with disproportionate megalencephaly subgroup was predominately driven by increases in GM and

274 This subgroup was representative of the larger MCAS-T cohort.

275 ostic yield across strategies and population subgroups was compared by use of nonparametric tests.

276 c analysis, the evolutionary relationship of subgroups was determined, delineating the divergence bet

277 ormulas that performed well in the short-eye subgroup were the Olsen (4-factor), Haigis, and Hill-rad

278 usion threshold and reading rate for the two subgroups were significantly different (p = .0009).

279 From the included studies, 85 subgroups were treated with CHOP, 76 with R-CHOP, and in

280 f 168 patients; 95% CI 67-80) and in disease subgroups were: 89% in newly diagnosed AML (62 of 70 pat

281 ifferences were due to the choroidal disease subgroup, which demonstrates significantly larger MFDS (

282 ations in southeastern Asia, nor whether the subgroup with a preference for rice and millet is presen

283 uals with disproportionate megalencephaly, a subgroup with higher rates of intellectual disability an

284 ith DSA and PRA > 10% were identified as the subgroup with significantly elevated responses.

285 Progression of Kmax was higher in subgroups with a baseline Kmax >58 diopters (n = 191) an

286 features can distinguish between HS and FTD subgroups with an accuracy of 76%.

287 bsolute risk reductions were also greater in subgroups with baseline coagulation biomarker levels at

288 tial mechanisms, and examine the efficacy in subgroups with clinically and genetically defined risk.

289 ells is able to separate CLL patients into 2 subgroups with different prognoses, but it does not cons

290 The model distinguished 5 subgroups with different recovery parameters ( r(1) = 0.

291 torization identified 3 HFpEF transcriptomic subgroups with distinctive pathways and clinical correla

292 ine learning of ECG waveforms identified CRT subgroups with relevance beyond LBBB and QRSd.

293 ught to enable the identification of patient subgroups with shared pathophysiology.

294 ween crystalline PCMs and one of the bonding subgroups (with the same bond length) found in amorphous

295 cer (TNBC) encompasses molecularly different subgroups, with a subgroup harboring evidence of defecti

296 39) overall and in 30 of the 36 prespecified subgroups, with estimated hazard ratios ranging from 1.1

297 series of diagnostic biopsies replicated the subgroups, with immune cell composition confirmed via im

298 lude that BPH consists of distinct molecular subgroups, with potential for subtype-specific precision

299 aracterized cognitive development trajectory subgroups within a schizophrenia sample and profiled the

300 with significantly higher recurrence risk in subgroups within Metroticket 2.0 criteria (P = 0.021) or